" /> " />

AstraZeneca PLC Earnings Estimate

AZN Stock  USD 67.75  0.51  0.75%   
The next projected EPS of AstraZeneca PLC is estimated to be 1.35 with future projections ranging from a low of 1.0 to a high of 1.96. AstraZeneca PLC's most recent 12-month trailing earnings per share (EPS TTM) is at 1.9. Please be aware that the consensus of earnings estimates for AstraZeneca PLC ADR is based on EPS before non-recurring items and includes expenses related to employee stock options.
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
AstraZeneca PLC is projected to generate 1.35 in earnings per share on the 30th of June 2024. AstraZeneca PLC earnings estimates module stress-tests analyst consensus about projected AstraZeneca PLC ADR EPS (Earning Per Share) to derive its highest and lowest estimates based on its historical volatility. Many public companies, such as AstraZeneca PLC, manage the perception of their earnings on a regular basis to make sure that analyst estimates are accurate. Future earnings calculations are also an essential input when attempting to value a firm. By analyzing AstraZeneca PLC's earnings estimates, investors can diagnose different trends across AstraZeneca PLC's analyst sentiment over time as well as compare current estimates against different timeframes. At this time, AstraZeneca PLC's Pretax Profit Margin is very stable compared to the past year. As of the 29th of March 2024, Operating Profit Margin is likely to grow to 0.22, while Gross Profit is likely to drop about 19.9 B.
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AstraZeneca PLC ADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation.

AstraZeneca PLC Earnings Estimation Breakdown

The calculation of AstraZeneca PLC's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of AstraZeneca PLC is estimated to be 1.35 with the future projection ranging from a low of 1.0 to a high of 1.96. Please be aware that this consensus of annual earnings estimates for AstraZeneca PLC ADR is based on EPS before non-recurring items and includes expenses related to employee stock options.
Last Reported EPS
0.0
1.00
Lowest
Expected EPS
1.35
1.96
Highest

AstraZeneca PLC Earnings Projection Consensus

Suppose the current estimates of AstraZeneca PLC's value are higher than the current market price of the AstraZeneca PLC stock. In this case, investors may conclude that AstraZeneca PLC is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and AstraZeneca PLC's stock will quickly adjusts to the new information provided by the consensus estimate.
Number of AnalystsHistorical AccuracyLast Reported EPSEstimated EPS for 30th of June 2024Current EPS (TTM)
586.19%
0.0
1.35
1.9

AstraZeneca PLC Earnings History

Earnings estimate consensus by AstraZeneca PLC ADR analysts from Wall Street is used by the market to judge AstraZeneca PLC's stock performance. Investors also use these earnings estimates to evaluate and project the stock performance into the future in order to make their investment decisions. However, we recommend analyzing not only AstraZeneca PLC's upcoming profit reports and earnings-per-share forecasts but also comparing them to our different valuation methods.

AstraZeneca PLC Quarterly Gross Profit

9.72 Billion

At this time, AstraZeneca PLC's Price Earnings Ratio is very stable compared to the past year. As of the 29th of March 2024, Price Earnings To Growth Ratio is likely to grow to 0.46, while Retained Earnings are likely to drop about 1.4 B. As of the 29th of March 2024, Net Income Applicable To Common Shares is likely to grow to about 3.2 B, while Common Stock Shares Outstanding is likely to drop about 2.9 B.
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of AstraZeneca PLC's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
66.4267.7369.04
Details
Intrinsic
Valuation
LowRealHigh
60.9874.8776.18
Details
Naive
Forecast
LowNextHigh
65.4566.7568.06
Details
13 Analysts
Consensus
LowTargetHigh
76.1883.7192.92
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as AstraZeneca PLC. Your research has to be compared to or analyzed against AstraZeneca PLC's peers to derive any actionable benefits. When done correctly, AstraZeneca PLC's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in AstraZeneca PLC ADR. Note that many institutional investors and large investment bankers can move markets due to the volume of AstraZeneca assets they manage. They also follow analysts to some degree and often drive overall investor sentiments towards AstraZeneca PLC. With so many stockholders watching consensus numbers, the difference between actual and projected earnings is one of the most critical factors driving AstraZeneca PLC's stock price in the short term.

AstraZeneca PLC Earnings per Share Projection vs Actual

Actual Earning per Share of AstraZeneca PLC refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering AstraZeneca PLC ADR predict the company's earnings will be in the future. The higher the earnings per share of AstraZeneca PLC, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.

AstraZeneca PLC Estimated Months Earnings per Share

For an investor who is primarily interested in generating an income out of investing in entities such as AstraZeneca PLC, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of AstraZeneca PLC should always be considered in relation to other companies to make a more educated investment decision.

AstraZeneca Quarterly Analyst Estimates and Surprise Metrics

Earnings surprises can significantly impact AstraZeneca PLC's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
null
nullnullnullnull
2024-02-08
2023-12-310.790.73-0.06
2023-11-09
2023-09-300.850.870.02
2023-07-28
2023-06-300.951.080.1313 
2023-04-27
2023-03-311.070.96-0.1110 
2023-02-09
2022-12-310.670.690.02
2022-11-10
2022-09-300.720.840.1216 
2022-07-29
2022-06-300.770.860.0911 
2022-04-29
2022-03-310.830.950.1214 
2022-02-10
2021-12-310.730.840.1115 
2021-11-12
2021-09-300.620.54-0.0812 
2021-07-29
2021-06-300.430.450.02
2021-04-30
2021-03-310.750.820.07
2021-02-11
2020-12-310.680.54-0.1420 
2020-11-05
2020-09-300.440.470.03
2020-07-30
2020-06-300.440.480.04
2020-04-29
2020-03-310.470.530.0612 
2020-02-14
2019-12-310.590.45-0.1423 
2019-10-24
2019-09-300.450.50.0511 
2019-07-25
2019-06-300.30.370.0723 
2019-04-26
2019-03-310.420.450.03
2019-02-14
2018-12-310.760.790.03
2018-11-12
2018-09-300.40.35-0.0512 
2018-07-26
2018-06-300.30.350.0516 
2018-05-18
2018-03-310.340.24-0.129 
2018-02-02
2017-12-310.470.650.1838 
2017-11-09
2017-09-300.550.560.01
2017-07-27
2017-06-300.420.440.02
2017-04-27
2017-03-310.40.50.125 
2017-02-02
2016-12-310.590.610.02
2016-11-10
2016-09-300.740.66-0.0810 
2016-07-28
2016-06-300.760.830.07
2016-04-29
2016-03-310.480.480.0
2016-02-04
2015-12-310.440.470.03
2015-11-05
2015-09-300.770.52-0.2532 
2015-07-30
2015-06-300.510.60.0917 
2015-04-24
2015-03-310.530.540.01
2015-02-05
2014-12-310.430.38-0.0511 
2014-11-06
2014-09-300.520.530.01
2014-07-31
2014-06-300.550.650.118 
2014-04-24
2014-03-310.620.59-0.03
2014-02-06
2013-12-310.610.620.01
2013-10-31
2013-09-300.630.61-0.02
2013-08-01
2013-06-300.580.60.02
2013-04-25
2013-03-310.670.710.04
2013-01-31
2012-12-310.70.780.0811 
2012-10-25
2012-09-300.740.760.02
2012-07-26
2012-06-300.680.770.0913 
2012-04-26
2012-03-310.890.910.02
2012-02-06
2011-12-310.780.810.03
2011-10-27
2011-09-300.840.860.02
2011-07-28
2011-06-300.910.87-0.04
2011-04-28
2011-03-311.081.120.04
2011-01-27
2010-12-310.670.70.03
2010-10-28
2010-09-300.750.750.0
2010-07-29
2010-06-300.80.90.112 
2010-04-29
2010-03-310.861.010.1517 
2010-01-28
2009-12-310.760.71-0.05
2009-10-29
2009-09-300.690.840.1521 
2009-07-30
2009-06-300.70.820.1217 
2009-04-30
2009-03-310.70.790.0912 
2009-01-29
2008-12-310.580.630.05
2008-10-30
2008-09-300.570.660.0915 
2008-07-31
2008-06-300.540.630.0916 
2008-04-24
2008-03-310.60.640.04
2008-01-31
2007-12-310.470.550.0817 
2007-11-01
2007-09-300.460.520.0613 
2007-07-26
2007-06-300.520.60.0815 
2007-04-23
2007-03-310.510.510.0
2007-02-01
2006-12-310.480.47-0.01
2006-10-26
2006-09-300.490.510.02
2006-07-27
2006-06-300.470.510.04
2006-04-27
2006-03-310.40.450.0512 
2006-02-02
2005-12-310.370.390.02
2005-10-27
2005-09-300.330.380.0515 
2005-07-28
2005-06-300.280.380.135 
2005-04-28
2005-03-310.290.320.0310 
2005-01-28
2004-12-310.290.30.01
2004-10-25
2004-09-300.260.280.02
2004-07-22
2004-06-300.240.250.01
2004-04-29
2004-03-310.270.24-0.0311 
2004-01-29
2003-12-310.20.19-0.01
2003-10-23
2003-09-300.170.240.0741 
2003-07-24
2003-06-300.170.20.0317 
2003-04-30
2003-03-310.210.270.0628 
2003-01-30
2002-12-310.210.230.02
2002-10-24
2002-09-300.180.20.0211 
2002-07-25
2002-06-300.240.23-0.01
2002-04-26
2002-03-310.240.280.0416 
2002-01-31
2001-12-310.230.890.66286 
2001-10-24
2001-09-300.210.240.0314 
2001-07-26
2001-06-300.210.210.0
2001-02-08
2000-12-310.210.210.0
2000-10-25
2000-09-300.230.19-0.0417 
1999-10-29
1999-09-300.170.190.0211 
1999-08-09
1999-06-300.260.410.1557 
1999-02-17
1998-12-310.240.250.01

About AstraZeneca PLC Earnings Estimate

The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of AstraZeneca PLC earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current AstraZeneca PLC estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as AstraZeneca PLC fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.'
Please read more on our stock advisor page.
Last ReportedProjected for 2024
Retained Earnings1.5 B1.4 B
Price Earnings Ratio 35.33  58.74 
Price Earnings To Growth Ratio 0.44  0.46 

Pair Trading with AstraZeneca PLC

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if AstraZeneca PLC position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in AstraZeneca PLC will appreciate offsetting losses from the drop in the long position's value.

Moving against AstraZeneca Stock

  0.48MGNX MacroGenics Financial Report 14th of May 2024 PairCorr
The ability to find closely correlated positions to AstraZeneca PLC could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace AstraZeneca PLC when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back AstraZeneca PLC - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling AstraZeneca PLC ADR to buy it.
The correlation of AstraZeneca PLC is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as AstraZeneca PLC moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if AstraZeneca PLC ADR moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for AstraZeneca PLC can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether AstraZeneca PLC ADR offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of AstraZeneca PLC's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Astrazeneca Plc Adr Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Astrazeneca Plc Adr Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AstraZeneca PLC ADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation.
Note that the AstraZeneca PLC ADR information on this page should be used as a complementary analysis to other AstraZeneca PLC's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.

Complementary Tools for AstraZeneca Stock analysis

When running AstraZeneca PLC's price analysis, check to measure AstraZeneca PLC's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AstraZeneca PLC is operating at the current time. Most of AstraZeneca PLC's value examination focuses on studying past and present price action to predict the probability of AstraZeneca PLC's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AstraZeneca PLC's price. Additionally, you may evaluate how the addition of AstraZeneca PLC to your portfolios can decrease your overall portfolio volatility.
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Commodity Directory
Find actively traded commodities issued by global exchanges
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Is AstraZeneca PLC's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AstraZeneca PLC. If investors know AstraZeneca will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AstraZeneca PLC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.059
Dividend Share
2.9
Earnings Share
1.9
Revenue Per Share
2.4547
Quarterly Revenue Growth
0.073
The market value of AstraZeneca PLC ADR is measured differently than its book value, which is the value of AstraZeneca that is recorded on the company's balance sheet. Investors also form their own opinion of AstraZeneca PLC's value that differs from its market value or its book value, called intrinsic value, which is AstraZeneca PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AstraZeneca PLC's market value can be influenced by many factors that don't directly affect AstraZeneca PLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AstraZeneca PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if AstraZeneca PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AstraZeneca PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.